Salmonella infection resistant composite probiotic agent and application thereof

Through the complex probiotic agents of Picocci lactate and Bacillus Veles, the problems of Salmonella infection and improvement of growth performance in avian animals have been solved, effectively inhibiting Salmonella and improving immune function, and the product is safe and not easy to develop resistance.

CN119060897APending Publication Date: 2024-12-03漯河微康农业生物科技有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411307119.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-19
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prevent and control Salmonella infection and improve the growth performance of avian animals, and there is a lack of microbial strategies for resisting Salmonella.

Method used

The complex probiotic agent of the Pediococcus acidilactici PA153 strain and Bacillus velezensis AMC102 strain was used to prevent and treat enteritis in avian animals and improve growth performance through complex methods.

Benefits of technology

It has achieved effective inhibition of Salmonella, improved the immune function and growth performance of avian animals, and has high product safety and is not easy to develop resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005049565900000061
    Figure BDA0005049565900000061
  • Figure BDA0005049565900000091
    Figure BDA0005049565900000091
  • Figure BDA0005049565900000101
    Figure BDA0005049565900000101
Patent Text Reader

Abstract

The invention relates to a composite probiotic agent capable of resisting salmonella infection and application of the composite probiotic agent. A bacterial strain in the composite probiotic agent is composed of a pediococcus acidilactici PA153 bacterial strain with the preservation number of CCTCC (China Center for Type Culture Collection) NO: M 2023230 and a bacillus velezensis AMC102 bacterial strain with the preservation number of CGMCC No.29826. The invention further relates to a preparation method of the composite probiotic agent capable of resisting salmonella infection and application of the composite probiotic agent capable of resisting salmonella infection. The PA153 strain and the AMC102 strain can cooperate with each other and promote each other, and have synergistic effects on resisting infection of pathogenic bacteria such as salmonella and the like, preventing and treating enteritis of poultry animals and improving growth performance of the poultry animals. Moreover, the two bacteria are probiotics, so that the product is high in safety and not easy to generate resistance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of probiotics and relates to a composite probiotic for resisting salmonella infection and application thereof. Background Art

[0002] In recent years, the side effects caused by the abuse of antibiotics in the aquaculture industry have become increasingly serious, so the importance of microbial feed additives in feed substitution and reducing the use of antibiotics has become more prominent. With the rapid development of research in the field of microorganisms, a large number of experimental studies have shown that lactic acid bacteria preparations can effectively inhibit the growth and reproduction of harmful intestinal bacteria, improve the body's immune function, and improve animal growth performance. It has been reported that Pediococcus acidilactici has the function of regulating the balance of animal flora and preventing stress diarrhea.

[0003] Salmonella is a conditional pathogen widely found in nature, and is also a common pathogen that threatens the healthy development of the poultry farming industry. In the current large-scale farming, whether it is broilers, laying hens, or poultry products, there is a risk of Salmonella. Salmonella enters the digestive tract of poultry through feed, invades the digestive system, causes intestinal infection of poultry, and leads to diseases such as diarrhea, which further causes poultry products to carry Salmonella and affect human health. Chickens of different ages will show different clinical characteristics after being infected with Salmonellosis. The younger the chicken, the more severe the symptoms and the higher the mortality rate.

[0004] Some lactic acid Pediococcus have been reported to have the function of regulating the immunity of farmed animals. Gene sequencing shows that lactic acid Pediococcus has no pathogenic genes and does not produce drug resistance. It is a green and safe feed additive strain. At present, there are few microbial strategies to resist Salmonella infection, so it is very necessary to develop more strategies to resist Salmonella infection, prevent and treat poultry enteritis, and improve the growth performance of poultry. Summary of the invention

[0005] In view of the deficiencies in the prior art, the object of the present invention is to provide a composite probiotic agent for resisting Salmonella infection and its application, specifically to provide a composite probiotic agent for resisting Salmonella infection, and its application in preparing a broad-spectrum antibacterial agent for intestinal infection flora, its application in preparing a product for resisting Salmonella infection, and its application in preparing a product for preventing and treating enteritis in poultry animals and improving the growth performance of poultry animals.

[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0007] In a first aspect, the present invention provides a composite probiotic for resisting Salmonella infection, wherein the strains in the composite probiotic are composed of Pediococcus acidilacticiPA153 strain with a preservation number of CCTCC NO: M 2023230 and Bacillus velezensis AMC102 strain with a preservation number of CGMCC No.29826.

[0008] The present invention develops a new probiotic compounding method and a new anti-Salmonella infection strategy, that is, Pediococcus acidilactici PA153 strain and Bacillus velezensis AMC102 strain are compounded for use, wherein the PA153 strain has excellent copolymerization ability, broad-spectrum antibacterial ability to intestinal infection flora, and prevents and treats poultry enteritis and improves poultry growth performance. Further, the present invention finds that the PA153 strain and the AMC102 strain can cooperate with each other, promote each other, and synergize in the effects of resisting infection by pathogenic bacteria such as Salmonella, preventing and treating poultry enteritis, and improving poultry growth performance. In addition, both bacteria are probiotics, the product is highly safe, and it is not easy to produce resistance.

[0009] Preferably, the ratio of the number of viable cells of the PA153 strain to that of the AMC102 strain is (3-10):1, for example 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, etc. Other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0010] Preferably, the total number of viable bacteria in the composite probiotic is not less than 1×10 8 CFU / g or 1×10 8 CFU / mL, for example 1×10 8 CFU / g (CFU / mL), 1×10 9 CFU / g (CFU / mL), 1×10 10 CFU / g (CFU / mL), 5×10 10 CFU / g (CFU / mL), 1×10 11 CFU / g (CFU / mL), 3×10 11 CFU / g (CFU / mL), 5×10 11 CFU / g (CFU / mL), 1×10 12 CFU / g (CFU / mL), 1×10 13CFU / g (CFU / mL), etc. Other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0011] Preferably, the dosage form of the composite probiotic includes solution, lyophilized powder, capsule, tablet or granule. The dosage form of the probiotic involved in the present invention is not limited, including the most commonly used solution, lyophilized powder, or further prepared capsule, tablet or granule.

[0012] Preferably, the dosage form of the composite probiotic preparation is a solution, which is prepared by the following method:

[0013] The PA153 strain and the AMC102 strain are inoculated into a culture medium respectively for activation and fermentation culture in sequence to obtain a fermentation broth; the fermentation broth is centrifuged respectively to obtain bacterial mud; the bacterial mud is mixed with PBS liquid or water and resuspended to obtain the composite probiotic preparation.

[0014] Preferably, the fermentation culture temperature is 35-40°C, for example, 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, etc.; the time is 12-30h, for example, 12h, 15h, 16h, 18h, 20h, 24h, 28h, 30h, etc.; other specific point values ​​within the above numerical range can be selected, and they will not be described one by one here.

[0015] Preferably, the inoculation amount is 1-5%, for example 1%, 2%, 3%, 4%, 5%, etc. Other specific point values ​​within the numerical range can be selected and will not be described one by one here.

[0016] Preferably, the composite probiotic preparation is in the form of a freeze-dried powder, which is prepared by the following method:

[0017] The PA153 strain and the AMC102 strain are inoculated into a culture medium respectively, activated and fermented in sequence to obtain a fermentation broth; the fermentation broth is centrifuged to obtain a bacterial sludge; the bacterial sludge is mixed with a protective agent and resuspended to obtain a resuspended liquid; the resuspended liquid is freeze-dried to obtain PA153 bacterial powder and AMC102 bacterial powder; the PA153 bacterial powder and the AMC102 bacterial powder are mixed according to the ratio of the number of live bacteria to obtain the composite probiotic preparation.

[0018] Preferably, the fermentation culture temperature is 35-40°C, for example, 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, etc.; the time is 12-30h, for example, 12h, 15h, 16h, 18h, 20h, 24h, 28h, 30h, etc.; other specific point values ​​within the above numerical range can be selected, and they will not be described one by one here.

[0019] Preferably, the inoculation amount is 1-5%, for example 1%, 2%, 3%, 4%, 5%, etc. Other specific point values ​​within the numerical range can be selected and will not be described one by one here.

[0020] Preferably, the composite probiotic further comprises a freeze-drying protectant and / or a functional auxiliary agent.

[0021] Preferably, the lyoprotectant comprises any one of skim milk, gelatin, dextrin, gum arabic, dextran, sodium alginate, polyvinyl pyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol, or a combination of at least two thereof.

[0022] In a second aspect, the present invention provides use of the composite probiotic agent described in the first aspect in the preparation of a broad-spectrum antibacterial agent for intestinal infection flora.

[0023] In a third aspect, the present invention provides use of the composite probiotic agent described in the first aspect in preparing a product for resisting Salmonella infection.

[0024] In a fourth aspect, the present invention provides use of the composite probiotic agent described in the first aspect in the preparation of a product for preventing and treating poultry enteritis and improving the growth performance of poultry.

[0025] Preferably, the product further contains auxiliary materials.

[0026] Preferably, the auxiliary materials include any one or a combination of at least two of fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, colorants, pH regulators, antioxidants, antibacterial agents or buffers.

[0027] Compared with the prior art, the present invention has the following beneficial effects:

[0028] The present invention develops a new probiotic compounding method and a new anti-Salmonella infection strategy, that is, Pediococcus acidilactici PA153 strain and Bacillus velezensis AMC102 strain are compounded for use, wherein the PA153 strain has excellent copolymerization ability, broad-spectrum antibacterial ability to intestinal infection flora, and prevents and treats poultry enteritis and improves poultry growth performance. Further, the present invention finds that the PA153 strain and the AMC102 strain can cooperate with each other, promote each other, and synergize in the effects of anti-Salmonella infection, prevention and treatment of poultry enteritis and improvement of poultry growth performance. In addition, both bacteria are probiotics, the product is highly safe, and it is not easy to produce resistance.

[0029] The PA153 strain involved in the present invention is classified and named Pediococcus acidilactici PA153, and the depositor is Wuhan University, Wuhan, China. The deposit time is March 2, 2023. The deposit number is CCTCC NO: M 2023230, and the address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0030] The AMC102 strain involved in the present invention is classified and named Bacillus velezensis, and the depository is the General Microbiology Center of China Microorganism Culture Collection Administration. The deposit time is January 31, 2024, the deposit number is CGMCC No.29826, and the address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. DETAILED DESCRIPTION

[0031] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0032] The PA153 strain involved in the following examples is classified and named Pediococcus acidilactici PA153, the preservation time is March 2, 2023, and the preservation number is CCTCC NO: M 2023230.

[0033] The AMC102 strain involved in the following examples is classified and named Bacillus velezensis, the preservation date is January 31, 2024, and the preservation number is CGMCC No.29826.

[0034] The preparation method of the PA153 or AMC102 bacterial suspension involved in the following experiment is as follows: the desired strain is inoculated into MRS liquid culture medium, cultured at 37°C for 18 hours for activation, and activated twice in succession to obtain an activated solution; the activated solution is inoculated into MRS liquid culture medium at an inoculum amount of 3% (v / v), and cultured at 37°C for 24 hours to obtain a bacterial solution; the bacterial solution is centrifuged at 4°C and 4000 rpm for 5 minutes, filtered to obtain bacterial bodies, and the bacterial bodies are resuspended in physiological saline.

[0035] MRS medium: peptone 10g / L, beef extract 10g / L, glucose 20g / L, sodium acetate 2g / L, yeast powder 5g / L, diammonium hydrogen citrate 2g / L, K2HPO4·3H2O 2.6g / L, MgSO4·7H2O 0.1g / L, MnSO4 0.05g / L, Tween 801mL / L, cysteine ​​hydrochloride 0.5g / L.

[0036] Example 1

[0037] Evaluation of coaggregation ability with Salmonella:

[0038] Coaggregation ability refers to the ability to eliminate gastrointestinal pathogen colonization by preventing pathogens from attaching to host tissues.

[0039] The Salmonella liquid was inoculated into LB medium and cultured in a shaking flask at 30°C for 16 h for later use.

[0040] The OD600 value of the PA153 bacterial suspension was adjusted to 0.6, and the OD600 value of the Salmonella solution was adjusted to 0.4. The mixture was fully shaken and mixed. The initial OD600 values ​​Ax and Ay were measured respectively. 20 mL of the PA153 bacterial suspension and the Salmonella solution were taken in equal volumes to a 50 mL centrifuge tube and mixed. After vortexing for 20 seconds, the mixture was incubated at 37°C. When the bacterial suspension was incubated for 2 hours, 5 hours, 21 hours, and 24 hours, 2 mL of the upper layer liquid was carefully drawn respectively, and the absorbance value (A) of the bacterial suspension at 600 nm was measured to calculate the coagulation of the PA153 strain and the Salmonella. Coagulation % = [(Ax+Ay) / 2-A(x+y)] / [(Ax+Ay) / 2]×100, where x and y represent the two strains, respectively, and (x+y) represents the mixture. The results are shown in Table 1.

[0041] Table 1

[0042]

[0043] From the results in Table 1, it can be seen that the PA153 strain involved in the present invention has excellent co-aggregation ability with Salmonella.

[0044] Example 2

[0045] Evaluation of broad-spectrum antibacterial activity:

[0046] The MRS medium containing 1.5% agar was cooled to 55°C and mixed with the suspensions of Escherichia coli, Salmonella, Staphylococcus aureus, Clostridium perfringens, Listeria monocytogenes, Clostridium difficile, Bacteroides fragilis, and Streptococcus pseudopneumoniae respectively to make the viable counts of the eight indicator bacteria to be 10 6 CFU / mL, and then quickly poured into the plate with the Oxford cup placed in advance. After the culture medium cooled and solidified, the Oxford cup was taken out and 200 μL of PA153 bacterial suspension or PA153 and AMC102 mixed bacterial suspension (the ratio of viable bacteria was 5:1) was injected into each well (the total number of viable bacteria in each group of bacterial suspensions was 10 8 CFU / mL), and after culturing at 37°C for 24 hours, the diameter of the inhibition zone (mm) was measured. The results are shown in Table 2.

[0047] Table 2

[0048] Indicator bacteria PA153 PA153+AMC102 Escherichia coli 20.83±0.23 28.47±0.47 Staphylococcus aureus 21.04±0.21 27.89±0.13 salmonella 22.83±0.40 30.67±0.17 Listeria monocytogenes 13.17±0.15 15.70±0.08 Clostridium difficile 10.05±0.18 13.46±0.07 Clostridium perfringens 14.66±0.25 18.69±0.05 Bacteroides fragilis 10.11±0.38 13.63±0.05 Streptococcus pseudopneumoniae 10.50±0.24 17.36±0.17

[0049] It can be seen from the data results in Table 2 that the PA153 strain involved in the present invention has excellent broad-spectrum antibacterial ability, and its broad-spectrum antibacterial ability is significantly improved after being compounded with the AMC102 strain.

[0050] Example 3

[0051] Impact on Salmonella infection in poultry:

[0052] (1) Experimental animals and grouping:

[0053] A total of 120 21-day-old white-feathered broilers with good health and similar body weight were randomly divided into 6 groups, with 2 independent replicates in each group and 10 chicks in each replicate. The 6 groups were blank control group (NC), model group (MC), PA153 intervention group, PA153+AMC102 intervention group 1, PA153+AMC102 intervention group 2, and ATCC8042+AMC102 intervention group. The experiment lasted for 21 days.

[0054] (2) Intervention methods:

[0055] (S1) The blank control group was fed a normal basal diet from day 1 and had free access to water until day 21;

[0056] (S2) The model group was fed with a normal basal diet and drinking water, and was orally gavaged with a suspension of Salmonella ATCC14028 (2×10 8 CFU / piece);

[0057] (S3) The PA153 intervention group was fed with a normal basal diet and drinking water, and was gavaged with PA153 suspension (2×10 8 CFU / each time), and the bacterial suspension of Salmonella ATCC14028 (2×10 8 CFU / piece);

[0058] (S4) PA153+AMC102 intervention group 1 was fed with a normal basal diet and drinking water, and was gavaged with PA153 and AMC102 suspensions (ratio of viable bacteria was 3:1, 2×10 8 CFU / each time), and the bacterial suspension of Salmonella ATCC14028 (2×10 8 CFU / piece);

[0059] (S5) PA153+AMC102 intervention group 2 was fed with a normal basal diet and drinking water, and was gavaged with PA153 and AMC102 suspensions every day from day 1 to day 21 (the ratio of viable bacteria was 10:1, 2×10 8 CFU / each time), and the bacterial suspension of Salmonella ATCC14028 (2×10 8 CFU / piece);

[0060] (S6) The ATCC8042+AMC102 intervention group was fed with a normal basal diet and drinking water, and was gavaged with commercially available ATCC8042 and AMC102 suspensions (ratio of viable bacteria was 10:1, 2×10 8 CFU / each time), and the bacterial suspension of Salmonella ATCC14028 (2×10 8 CFU / each).

[0061] (3)Indicator analysis:

[0062] (3.1) The weight and feed consumption of the chickens were recorded every day, and the daily weight gain (g / day) and daily feed intake (g / day) were calculated, and the feed-to-weight ratio was calculated. The results are shown in Table 3.

[0063] Table 3

[0064]

[0065] It can be seen from the data in Table 3 that, compared with the model group, intervention with PA153 strain or combined intervention with PA153 strain and AMC102 strain can effectively alleviate the harm of Salmonella to chickens and improve the growth performance of chickens, and the effect of the combined intervention group is better.

[0066] (3.2) After the experiment, 10 broilers in each group were randomly killed and dissected, and the intestinal tissue was taken to prepare the small intestinal tissue homogenate supernatant. The levels of TGF-β, IL-6, IL-17, serum ferritin (ST), and immunoglobulin A (IgA) were detected using ELISA kits. The results were expressed as the cytokine concentration per milliliter of small intestinal tissue homogenate supernatant using the standard cytokines provided in the kit. The results are shown in Table 4.

[0067] Table 4

[0068]

[0069] It can be seen from the data in Table 4 that compared with the model group, after intervention with PA153 strain or combined intervention with PA153 strain and AMC102 strain, the expression of inflammatory factors can be reduced and the expression of immunoglobulins can be increased, indicating that the harm of Salmonella to chickens can be effectively alleviated and the immunity of chickens can be improved, and the effect of the combined intervention group is better.

[0070] The applicant declares that the present invention illustrates the technical solution of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0071] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0072] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. A composite probiotic for resisting salmonella infection, characterized in that: The strains in the composite probiotics are composed of Pediococcus acidilactici PA153 strain with a preservation number of CCTCC NO: M 2023230 and Bacillus velezensis AMC102 strain with a preservation number of CGMCC No.29826.

2. The composite probiotic according to claim 1, characterized in that The ratio of the number of viable bacteria of the PA153 strain to that of the AMC102 strain is (3-10):

1.

3. The composite probiotic according to claim 1, characterized in that The total number of viable bacteria in the composite probiotic is not less than 1×10 8 CFU / g or 1×10 8 CFU / mL.

4. The composite probiotic according to claim 1, characterized in that The dosage form of the composite probiotic includes solution, lyophilized powder, capsule, tablet or granule.

5. The composite probiotic according to claim 1, characterized in that: The composite probiotics further include a freeze-drying protective agent and / or a functional auxiliary agent.

6. The composite probiotic according to claim 5, characterized in that: The lyoprotectant includes any one of skim milk, gelatin, dextrin, gum arabic, dextran, sodium alginate, polyvinyl pyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol, or a combination of at least two thereof.

7. Use of the composite probiotic according to any one of claims 1 to 6 in the preparation of a broad-spectrum antibacterial agent for intestinal infection flora.

8. Use of the composite probiotic according to any one of claims 1 to 6 in the preparation of products for resisting Salmonella infection.

9. Use of the composite probiotic according to any one of claims 1 to 6 in the preparation of products for preventing and treating enteritis in poultry animals and improving the growth performance of poultry animals.

10. The use according to claim 8 or 9, characterized in that: The product also contains excipients; Preferably, the auxiliary materials include any one or a combination of at least two of fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, colorants, pH regulators, antioxidants, antibacterial agents or buffers.